LONA Leonia Pharma — The Case for $200

I view the **“New Leonia”** (post-December 18, 2025) as a fundamentally different animal than the company that struggled with its Alzheimer’s data. By acquiring **Lasofoxifene**, Leonia has executed a *pipe-cleaner* move—pivoting from the high-risk, high-failure world of neurodegeneration to a de-risked, Phase 3 oncology asset with a clear path to **$1B+ in peak sales**. # 1. Asset Analysis: Lasofoxifene (The “Crown Jewel”) **Lasofoxifene** is a Selective Estrogen Receptor Modulator (SERM). Unlike existing treatments (SERDs) that destroy the estrogen receptor, Lasofoxifene *modulates* it. **Target Population:** Specifically **ER+/HER2- metastatic breast cancer patients with an ESR1 mutation**. This mutation is the *arch-nemesis* of standard care, appearing in \~40% of patients who fail initial therapies. **The “Unfair Advantage”:** Because it is a SERM, it acts as an antagonist in the breast (killing cancer) but an agonist in the bone and vagina. **Quality of Life:** Most cancer drugs cause bone loss and severe vaginal atrophy. Lasofoxifene improves them. In a **$17B market**, this *tissue-selective* benefit is a massive commercial differentiator. **Clinical Strength:** In Phase 2 (**ELAINE-2**), the combination of **Lasofoxifene + Abemaciclib** showed a **13-month median Progression-Free Survival (PFS)**. For comparison, current standard combinations in this setting often struggle to clear **7–9 months**. # 2. Financial Rebirth The acquisition deal on **Dec 18, 2025**, completely restructured **Leonia’s** balance sheet: * **Fresh Capital:** Secured **$90M upfront**, with a path to **$236M total** through warrants. * **Valuation Gap:** At **$7.48**, the market cap is roughly **$29M**. This is an absurdity in biotech—**LONA is trading at a \~70% discount to its cash alone**, essentially giving you the Phase 3 asset for *negative dollars*. * **Runway:** Current funding extends the company into **2028**, fully covering the **mid-2027 Phase 3 (ELAINE-3) data readout**. # 3. 5-Year Price Target Analysis (2026–2030) Biotech valuations typically follow a **step-function model** based on clinical milestones. # Phase 1: The Accumulation Year (2026) **Target:** $12.00 – $15.00 **Driver:** Institutional re-rating. As the market realizes **Leonia** has a legitimate Phase 3 oncology program backed by heavyweights like **Perceptive Advisors** and **Commodore Capital**, the distress discount evaporates. The stock should trade toward its cash value (\~$25/share), though warrant dilution keeps pricing in the mid-teens. # Phase 2: The Catalyst Year (2027) **Target:** $35.00 – $45.00 **Driver:** **ELAINE-3 Phase 3 data (mid-2027)**. Success validates a **$1B+ peak sales drug**. Oncology companies with positive Phase 3 data routinely command **$1B–$2B market caps**. Even with a diluted **15–20M share count**, $40+ is conservative. # Phase 3: Commercialization & M&A (2028–2030) **Target:** $75.00 – $100.00 **Driver:** FDA approval and commercial launch. If Lasofoxifene becomes the **standard of care** for ESR1-mutant breast cancer, **Leonia** becomes a prime acquisition target for: * **Eli Lilly** (already supplying Abemaciclib) * **Pfizer** (original developer of Lasofoxifene) # Summary of Analysis |Metric|2025 Value|2030 Projection| |:-|:-|:-| |Asset Status|Phase 3 (Mid-Enrollment)|Marketed / M&A Target| |Cash Position|\~$110M (Post-Financing)|Cash-Flow Positive or Acquired| |Market Cap|\~$29M|$1.5B – $2.5B| |Price Target|$7.48|**$85.00**| **Risk Note:** The primary risk is the **ELAINE-3 Phase 3 data**. Failure to demonstrate superiority over Fulvestrant likely sends the stock back to *cash-shell values* (\~$4). However, given the Phase 2 strength, the **risk/reward asymmetry is exceptional**. # ATH-1105: Leonia’s “Dark Horse” Neurodegeneration Asset While **Leonia Pharma (LONA)** has pivoted toward oncology, **ATH-1105** remains its high-potential optionality in neurodegeneration. I categorize **ATH-1105** as a **next-generation HGF modulator**, designed to fix the weaknesses of the company’s prior drug, **fosgonimeton**. # 1. Asset Analysis: ATH-1105 * **Indication:** ALS * **Modality:** Orally available small molecule * **Mechanism:** Positive modulation of the **Hepatocyte Growth Factor (HGF) system** In ALS, neurons die because protective signaling collapses. ATH-1105 aims to restore this signaling, acting as a **neuroprotective shield** to slow motor neuron death and reduce neuroinflammation. # The TDP-43 Advantage Over **97% of ALS cases** involve toxic **TDP-43 protein aggregation**. Preclinical 2025 data showed: * Significant **reduction of TDP-43 pathology** * Meaningful **motor function improvement** in ALS mouse models # Phase 1 Success (Aug 2025) * **80 healthy volunteers** * Safe, well-tolerated * **CNS-penetrant** * Crosses the blood-brain barrier at dose-proportional levels # 2. Clinical Catalyst & Patient Population * **Phase 2 Start:** Late 2025 / Early 2026 * **Design:** Biomarker-driven * **Primary Focus:** **Neurofilament Light Chain (NfL)** NfL is a validated biomarker of neuronal damage. A meaningful reduction in humans would represent a **major de-risking event**. # ALS Market * \~$900M global market (2025) * Severely underserved * Current therapies extend life by only months A disease-modifying ALS therapy with a **TDP-43 mechanism** would likely achieve **blockbuster status**. # 3. Valuation & Price Target (ATH-1105) # Current Financial Context (Dec 2025) * **Share Price:** \~$7.48 * **Cash:** \~$110M * **Enterprise Value:** Negative The market is assigning *less than zero value* to: * A Phase 3 oncology asset * A Phase 2-ready ALS program # 24-Month Price Target **$22.00 – $28.00** **Driver:** Positive Phase 2 ALS biomarker data (NfL reduction) Successful mid-stage ALS assets typically command **$400M–$600M valuations**. # 5-Year Price Target **$60.00 – $90.00** **Driver:** Phase 3 success + FDA approval Disease-modifying ALS drugs are valued on **billion-dollar peak sales assumptions**. # Analyst Verdict **ATH-1105 is pure optionality.** # Bull Case You are buying: * A **Phase 3 breast cancer drug** for free (cash discount) * Plus a **high-science ALS asset** with strong Phase 1 data # Bear Case ALS remains brutally difficult. If Phase 2 fails to move NfL, ATH-1105’s value drops to zero, and **LONA becomes a single-asset oncology company**.